AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14688490
Drug: Combination drug
RxNorm normalized name: combination drugs used in erectile dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination drug therapy
Trial: 20875125
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment group (lunchtime walking intervention)
Trial: 18230943
Drug: Rogerian Supportive
RxNorm normalized name: geranium oil, Algerian type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rogerian Supportive Therapy (ST)
Trial: 14639584
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) with 0.2 mg/kg of alpha‐galactosidase A every 2 weeks
Trial: 10952699
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid volumes (60 ml/kg on day 1 progressing to 150 ml/kg on day 7)
Trial: 1298545
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg once a day (n=13)
Trial: 1298545
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg once a day + Gemfibrozil 600 mg daily (n=11)
Trial: 7582386
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg once a day
Trial: 1298545
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg once a day + Gemfibrozil 600 mg daily
Trial: 6209346
Drug: Presurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presurgical treatment with 3.5 X 10(4) units of leukocyte interferon/kg (3 injections)
Trial: 6209346
Drug: Postsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postsurgical treatment with placebo (7 injections)
Trial: 6209346
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 injections)
Trial: 31257591
Drug: AMX +
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMX + MET (500 mg three times a day and 400 mg three times a day for 7 days)
Trial: 31257591
Drug: CLM (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLM (500 mg twice a day for 7 days)
Trial: 12042231
Drug: Brief cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive-behavioural therapy (CBT), n=257
Trial: 12042231
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control group), n=165
Trial: 10192710
Drug: BCG vaccine
RxNorm normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine given simultaneously with DTaP vaccine
Trial: 7762855
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg diltiazem
Trial: 15502049
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg lidocaine
Trial: 1702899
Drug: Isoprinosine 3
RxNorm normalized name: Isoprénaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoprinosine 3 g/day for 28 days
Trial: 6775742
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of papaveretum (1 mg/min loading dose, followed by 8 times the loading dose over 48 hours)
Trial: 6775742
Drug: Intermittent intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intramuscular dose of papaveretum (0.25 mg/kg at four hourly intervals as necessary)
Trial: 31886526
Drug: Pharmaceutical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical and other innovative therapeutic strategies
Trial: 16961448
Drug: 3-S therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-S therapy (8 weeks)
Trial: 10697060
Drug: Estrogen 1.25
RxNorm normalized name: Conjugated estrogen 1.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen 1.25 mg/d
Trial: 3544189
Drug: Low-dose antacid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose antacid (400 mg of aluminum hydroxide plus 400 mg of magnesium hydroxide four times a day)
Trial: 3544189
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (cimetidine and low-dose antacid)
Trial: 30388194
Drug: Tafenoquine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine (n = 12), single 200-mg dose on days 1, 2, 3, and 10
Trial: 22914392
Drug: Progesterone treatment
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone treatment (n=258)
Trial: 22914392
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n=265)
Trial: 19892086
Drug: Manualized and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualized and workbook-driven individual cognitive-behavioral treatment for social anxiety disorder
Trial: 19892086
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment for 20 weeks
Trial: 17684877
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Trial: 17684877
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Trial: 17684877
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg hyperbaric bupivacaine 0.5% + 25 microg fentanyl
Trial: 9650877
Drug: Herbal extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal extract mouthwash (6.3 mg/ml)
Trial: 8583518
Drug: Recovery Attitude
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery Attitude and Treatment Evaluator (RAATE) completed by patients
Trial: 8583518
Drug: Recovery Attitude
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery Attitude and Treatment Evaluator (RAATE) completed by clinicians
Trial: 8583518
Drug: Less than
RxNorm normalized name: IgA less than or equal to 50 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less than 1 month of treatment
Trial: 2678688
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon (100 x 10(6) IU)
Trial: 2678688
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon (10 x 10(6) IU)
Trial: 10208143
Drug: Oxandrolone, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone, 20 mg/d
Trial: 7885427
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patches (15 mg for 16 hours daily)
Trial: 356980
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus DTIC and actinomycin D (starting at 650 mg/m2 and 1 mg/m2 respectively, courses repeated at 3-4 week intervals)
Trial: 30538068
Drug: Systemic therapy-naive
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy-naive patients with BM
Trial: 30538068
Drug: Patients developing
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients developing BM while on first-line systemic therapy
Trial: 30538068
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without BM while on first-line systemic therapy
Trial: 27756786
Drug: LHRH agonist/bicalutamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist/bicalutamide
Trial: 24119182
Drug: Carvedilol 12.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 12.5/25 mg daily
Trial: 24119182
Drug: Metoprolol 50/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50/100 mg daily
Trial: 24119182
Drug: Nebivolol 2.5/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 2.5/5 mg daily
Trial: 21428248
Drug: Metronidazole vaginal
RxNorm normalized name: MetroNIDAZOLE Vaginal
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole vaginal suppository 1/night for 1 week
Trial: 21428248
Drug: Econazole vaginal
RxNorm normalized name: econazole Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Econazole vaginal suppository 1/night for 3 days
Trial: 19427775
Drug: Crocus sativus
RxNorm normalized name: CROCUS SATIVUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocus sativus (saffron) 200mg tablet taken daily for ten days
Trial: 16997936
Drug: DHEA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA treatment (75 mg daily for an average of 17.6 weeks)
Trial: 363252
Drug: Additional early
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional early therapy
Trial: 19420003
Drug: Single intracoronary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intracoronary infusion of bone marrow mononuclear cells (BMC) (1.9 +/- 1.2 x 10^8) at 3-7 days after AMI
Trial: 19420003
Drug: BMC administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BMC administration both at 3-7 days (2.0 +/- 1.4 x 10^8) and at 3 months (2.1 +/- 1.7 x 10^8)
Trial: 19420003
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection at 3-7 days
Trial: 14736927
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy (at least 240 mg/m²); 932 patients assigned to chemotherapy
Trial: 9784911
Drug: Dipyridamole (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (300 mg/d) for 6 months
Trial: 9784911
Drug: Dilazep (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilazep (300 mg/d) for 6 months
Trial: 2832764
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with thoracic irradiation (protocol 78 LUN 328)
Trial: 2832764
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with simultaneous radiotherapy (protocol LUN 81343)
Trial: 2832764
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy alone (control group)
Trial: 22332908
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg trans-resveratrol twice daily for 12 weeks
Trial: 22332908
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg trans-resveratrol twice daily for 12 weeks
Trial: 2145874
Drug: UK 69,578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK 69,578 (atriopeptidase inhibitor) administered as an intravenous infusion over 20 min
Trial: 2145874
Drug: UK 69,578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK 69,578 (atriopeptidase inhibitor)
Trial: 620911
Drug: Cimetidine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (0.8 to 1.2 g daily for 2 to 6 weeks)
Trial: 620911
Drug: Cimetidine therapy
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine therapy cessation
Trial: 620911
Drug: Chronic or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic or intermittent cimetidine therapy
Trial: 27803139
Drug: TNF-α inhibitors
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNF-α inhibitors (Infliximab and Etanercept)
Trial: 24673513
Drug: Benvitimod (0.5-2.0%)
RxNorm normalized name: Benvitimod
DrugBank: Tapinarof (DB06083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benvitimod (0.5-2.0%) cream, doses escalated from 5 to 30 mg daily, applied once or twice daily
Trial: 24673513
Drug: Benvitimod (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benvitimod (5 mg q.d and b.i.d)
Trial: 22988684
Drug: In-office treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office treatment with desensitizing paste containing 8% arginine and calcium carbonate, followed by brushing with desensitizing toothpaste containing 8% arginine, calcium carbonate with 1450 ppm fluoride for 24 weeks.
Trial: 20174763
Drug: Antiplatelet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet treatment (overall)
Trial: 17431110
Drug: Lonafarnib (Farnesyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lonafarnib (Farnesyl transferase inhibitor)
Trial: 15867580
Drug: 5‐ASA MMx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA MMx (1.2 g three times per day)
Trial: 15867580
Drug: 5‐ASA enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA enema (4 g)
Trial: 16679206
Drug: Long buccal-segment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long buccal-segment group (canines, both premolars, and first molars)
Trial: 16679206
Drug: Short buccal-segment
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short buccal-segment group (only maxillary first molars)
Trial: 10826565
Drug: High sodium
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High sodium diet with L-NMMA infusion (1.8 mg/kg over 30 min)
Trial: 10826565
Drug: Low sodium
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium diet with L-NMMA infusion (1.8 mg/kg over 30 min)
Trial: 8858747
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (5 g/day)
Trial: 8858747
Drug: Carbohydrate-reduced diet
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-reduced diet (84 g/day)
Trial: 6507509
Drug: Diuretics continued
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics continued throughout pregnancy
Trial: 6507509
Drug: Diuretics discontinued
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics discontinued immediately
Trial: 27463412
Drug: Low-lactose skimmed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-lactose skimmed milk enriched with 40 mg/100 mL of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA), 0.54 g/100 mL oleic acid, and vitamins (n = 63)
Trial: 19609570
Drug: Physical activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical activity intervention (home-based aerobic and light resistance training program, weekly group sessions)
Trial: 18756746
Drug: Structural resonance
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structural resonance electromagnetic therapy (SREMT) in the basic group
Trial: 18756746
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug and physiotherapeutic treatment
Trial: 15925962
Drug: Sublingual buprenorphine
RxNorm normalized name: buprenorphine Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual buprenorphine and Oral methadone
Trial: 12872590
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser treatment (100 mJ/pulse and 10 Hz)
Trial: 12872590
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (untreated implants)
Trial: 1906441
Drug: Chronic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chronic low-dose TRH therapy
Trial: 30902753
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of oral tranexamic acid (TXA) 2 h preoperatively
Trial: 30902753
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of oral tranexamic acid (TXA) 4 h postoperatively
Trial: 30902753
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of oral tranexamic acid (TXA) at 4, 10, and 16 h postoperatively
Trial: 23260261
Drug: Ranibizumab (RBZ)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (RBZ) 0.3 mg
Trial: 23260261
Drug: Ranibizumab (RBZ)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab (RBZ) 0.5 mg
Trial: 23260261
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to 0.5 mg RBZ from sham at month 6
Trial: 17644340
Drug: Encapsulated phytosterol
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated phytosterol esters (2.6 g for 12 weeks)
Trial: 15100522
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol solution
Trial: 11562614
Drug: Tobramycin for
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin for inhalation
Trial: 8163364
Drug: Estraderm TTS
RxNorm normalized name: ESTRADERM TTS
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estraderm TTS 50 patches
Trial: 28882773
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave treatment (ESWT) plus specific exercise programme
Trial: 20673296
Drug: Partial implant-supported
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial implant-supported prosthesis
Trial: 20673296
Drug: No implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No implants (control group)
Trial: 19262561
Drug: Caltrate D
RxNorm normalized name: Caltrate Plus D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caltrate D (1 pill daily)
Trial: 15319704
Drug: Ropinirole (1.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (1.45 mg/d mean dosage)
Trial: 15319704
Drug: Levodopa sustained
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa sustained release (190 mg/d mean dosage)
Trial: 11167169
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion with fentanyl (19.2+/‐5.2 microg x h(‐1))
Trial: 11167169
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion without fentanyl
Trial: 9024025
Drug: Acupressure bands
RxNorm normalized name: Band-Aid Hurt-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure bands + 2 mL IV saline
Trial: 9024025
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg IV metoclopramide + placebo wrist bands
Trial: 9024025
Drug: Placebo wrist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo wrist bands + 2 mL IV saline
Trial: 8275615
Drug: Valaciclovir (256U87)
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valaciclovir (256U87) at doses from 100 to 1000 mg (single-dose study)
Trial: 8275615
Drug: Valaciclovir (256U87)
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valaciclovir (256U87) at doses from 250 to 2000 mg (multiple-dose study)
Trial: 3546605
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) therapy
Trial: 23473238
Drug: Multimodal coma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal coma stimulation twice a day (50 minutes each session)
Trial: 23473238
Drug: Conventional physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physiotherapy twice daily
Trial: 16935774
Drug: EGFR tyrosine
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EGFR tyrosine kinase inhibitors
Trial: 16935774
Drug: EGFR tyrosine
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EGFR tyrosine kinase inhibitors plus aromatase inhibitors